Enzo Biochem Q4 Revenues Up 4 Percent on Increased Lab Services Revenues | GenomeWeb

NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Thursday that its fourth quarter revenues rose 4 percent year over year, thanks to an increase in revenues from its clinical laboratory services business.

For the three-month period ended July 31, the molecular diagnostics company reported revenues of $26.6 million, up from $25.7 million a year earlier.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.